Guardant Health Ordered to Pay $245.2M in Patent Case
Table of Contents
Guardant Health has been ordered by a U.S. District Court in Delaware to pay over $245.2 million to TwinStrand Biosciences and the University of Washington for patent infringement. This ruling represents a historic victory for academic research and its commercial licensees, who successfully defended their proprietary DNA sequencing technology in a high-stakes legal battle. The final judgment, entered on August 21, 2026, by Judge Gregory B. Williams, solidifies a November 2023 federal jury verdict that found Guardant Health willfully infringed two foundational patents covering ultra-accurate genomic sequencing. This landmark legal resolution sends massive U.S. economic shockwaves through the molecular diagnostics and precision oncology sectors.
Introduction to the Delaware Court Final Judgment
The final judgment entered in the Delaware District Court is the culmination of a multi-year intellectual property battle that began in 2021. The plaintiffs, TwinStrand Biosciences and the University of Washington, argued that Guardant Health built its highly lucrative oncology testing empire by copying patented technology without a license. The technology at the center of the dispute, Duplex Sequencing, allows clinical laboratories to detect rare genetic mutations from blood-drawn cell-free DNA (cfDNA) with unprecedented sensitivity.
By upholding the original jury verdict, the court has made it clear that commercial developers cannot bypass the patent rights of academic institutions and the startups that license them. While Guardant Health has signaled its intention to appeal the decision, the comprehensive scope of the final judgment significantly limits their immediate maneuvers. This ruling establishes a powerful precedent for intellectual property rights within the biotechnology community, demonstrating that federal courts are prepared to award substantial damages to safeguard fundamental scientific innovations.
Breaking Down the $245.2 Million Damages Award
The court’s final award of $245.2 million is structured across several distinct categories to account for past infringement, ongoing sales during litigation, and interest accrued over the years. Rather than a flat penalty, the award reflects a meticulous accounting of Guardant’s revenues from its clinical sequencing business.
| Damages Category | Amount (USD) | Period / Details |
|---|---|---|
| Past Infringement Damages | $83.4 Million | Inception through June 30, 2023 (Original jury verdict) |
| Supplemental Damages | $19.5 Million | Sales from July 1, 2023, to February 5, 2024 |
| Accrued Royalties | $119.4 Million | Sales from February 5, 2024, to May 31, 2026 (6% rate) |
| Pre- and Post-Judgment Interest | $22.9 Million | Interest accrued on unpaid damages and royalties |
| Total Final Judgment Award | $245.2 Million | Ordered by Delaware District Court on August 21, 2026 |
| Future Royalty Rate | 6% quarterly | On 11 covered products through March 15, 2033 |
Past Damages and Supplemental Calculations
The core of the financial judgment is built upon the jury’s original November 2023 verdict, which awarded TwinStrand and the University of Washington $83.4 million for Guardant’s infringement through June 30, 2023. To account for the time elapsed between that jury verdict and the entry of final judgment, the court calculated supplemental damages of $19.5 million. This portion of the award covers Guardant’s continued unauthorized sales of covered oncology tests from July 1, 2023, through February 5, 2024. The court’s meticulous calculation process is reminiscent of the strict procurement rules overseen by the Defense Department, which enforces strict compliance and licensing protocols across high-technology frameworks.
Accrued Royalties and Interest Determinations
Because Guardant continued to market its products while litigation progressed, the court also awarded $119.4 million in accrued royalties for the period between February 5, 2024, and May 31, 2026. This figure was determined by applying a 6% royalty rate to the revenue generated by the infringing products, which represented approximately 90% of Guardant’s total corporate revenue during that timeframe. Finally, $22.9 million in pre-judgment and post-judgment interest was added to ensure the plaintiffs were fully compensated for the loss of capital use over time. Additionally, Guardant must continue to pay a quarterly 6% royalty on all covered product sales until the patents expire on March 15, 2033.
The Science Behind Duplex Sequencing Technology
To fully appreciate the commercial and legal impact of this ruling, one must understand the biochemistry of Duplex Sequencing. Traditional next-generation sequencing (NGS) has vastly improved genomic analysis, but it remains limited by an inherent error rate of roughly 1 in 100 to 1 in 1,000 sequenced bases. While sufficient for mapping a standard genome, this background noise makes it nearly impossible to identify rare cancer mutations present at ultra-low frequencies in circulating blood plasma.
Why Duplex Sequencing Outperforms Standard Next-Generation Sequencing
Duplex Sequencing bypasses standard sequencing limitations by independently reading both complementary strands of a single double-stranded DNA molecule. Because any true biological mutation must be present on both strands of the DNA duplex, comparing the sequences of the two complementary strands allows researchers to filter out PCR duplication errors and chemical sequencing artifacts. This method improves accuracy by up to 10,000-fold. The clinical impact of this technology in oncology is as revolutionary as cutting-edge semiconductor advancements are for deep learning neural networks, turning raw genomic sequencing data into highly precise clinical roadmaps.
The Core Patents at the Center of the Dispute
The lawsuit centered on U.S. Patent Nos. 10,287,631 and 10,760,127, both of which are owned by the University of Washington and exclusively licensed to TwinStrand Biosciences. These patents describe the chemical and computational methods used to tag DNA molecules with degenerate molecular identifiers, amplify the tagged molecules, sequence them, and compile consensus sequences from the dual complementary strands. Developed in the early 2010s by Dr. Jesse Salk and his colleagues while conducting research at the University of Washington, this technology became the core foundation upon which TwinStrand was built.
Historical Timeline of the Litigation and Verdicts
The journey to the $245.2 million final judgment has been a long and contentious legal campaign. TwinStrand and the University of Washington first filed the patent infringement lawsuit against Guardant Health in 2021. In response, Guardant launched aggressive counterclaims and actively sought to invalidate the patents through Inter Partes Review (IPR) at the Patent Trial and Appeal Board (PTAB).
However, in October 2023, the PTAB rejected all of Guardant’s invalidity challenges, confirming the integrity of the university’s patent claims. This cleared the path for a jury trial in the U.S. District Court of Delaware. In November 2023, the jury ruled in favor of TwinStrand, finding that Guardant had willfully infringed the patents. Guardant subsequently filed post-trial motions attempting to overturn the jury’s verdict or secure a new trial. Judge Williams systematically denied all of those motions, leading directly to the final judgment entered on August 21, 2026.
Impact on Guardant Health’s Oncology Product Portfolio
The Delaware court’s final judgment covers 11 of Guardant Health’s most prominent commercial products and services. This includes its flagship product, Guardant360 CDx, which was the first FDA-approved comprehensive genomic profiling liquid biopsy test. Other covered tests subject to the 6% quarterly royalty include Guardant Reveal (designed for detection of minimal residual disease), GuardantOMNI, Guardant HEME, GuardantINFINITY, Guardant LUNAR-2, and several others.
Paying a 6% royalty on almost its entire revenue generator through March 2033 represents a serious headwind for Guardant Health. It will likely squeeze corporate profit margins at a time when oncology laboratories must navigate rising health benefit cost structures and complex national insurance coverage policies. Additionally, Guardant is now legally mandated to provide TwinStrand and the University of Washington with detailed quarterly accounting of all domestic sales, forcing an unprecedented level of operational transparency.
Broader Consequences for the Precision Medicine Industry
The outcome of this case has sent shockwaves throughout the wider biotechnology sector. For academic research institutions, the verdict represents a major milestone. It highlights how academic laboratories can successfully protect their discoveries and realize substantial financial value by licensing breakthroughs to targeted biotech startups. This victory stands as a model of small business success, showing that innovative startups can use patent law as a shield to compete with much larger industry players.
Furthermore, the case may influence future government policy regarding the regulation and validation of laboratory-developed tests (LDTs). Diagnostic developers will need to proceed with extreme caution, ensuring they have secure freedom-to-operate clearances before commercializing advanced sequencing panels. Just as technology companies are investing in green energy projects to secure critical supply chains, biotechnology firms must aggressively license or co-develop intellectual property to avoid crippling court injunctions and multi-million dollar damages awards.
This case is part of a broader trend of high-stakes corporate legal battles in healthcare. It mirrors other major conflicts, such as the ongoing multibillion-dollar healthcare litigation that continues to redefine product liabilities and alter the strategic priorities of multinational medical corporations. As Guardant prepares to take its case to the Federal Circuit Court of Appeals, the diagnostics industry will be watching closely to see if this historic $245.2 million judgment will be upheld.
